Baidu
map

NAT COMMUN:沈少明/陈国强合作报道核内PTEN降解促进肿瘤发生

2020-04-19 MedSci原创 MedSci原创

最近,在发现核PTEN比细胞质PTEN更不稳定的基础上,我国研究人员发现F-box only蛋白22(FBXO22)在赖氨酸221处诱导核PTEN的泛素化,而非细胞质PTEN的泛素化。

PTEN的核定位对其肿瘤抑制作用至关重要,在多种癌症中,核PTEN的缺失比细胞质PTEN更突出。然而,核内PTEN的特异性调控机制却鲜有报道。

最近,在发现核PTEN比细胞质PTEN更不稳定的基础上,我国研究人员发现F-box only蛋白22(FBXO22)在赖氨酸221处诱导核PTEN的泛素化,而非细胞质PTEN的泛素化,从而导致核PTEN的降解。FBXO22通过泛素化和降解核PTEN发挥了促进肿瘤的作用。

此外,FBXO22在各种癌症类型中过量表达,并在结直肠癌组织中促进核PTEN下调。

综上所述,本研究报告了特异性调控核PTEN稳定性的机制,为开发治疗策略提供了机会,旨在实现PTEN作为肿瘤抑制剂的完全再激活。

 

原始出处:

Meng-Kai Ge et al. FBXO22 degrades nuclear PTEN to promote tumorigenesis. NAT COMMUN, 2020.

 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1884260, encodeId=2687188426049, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Oct 19 21:23:12 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087679, encodeId=a351208e679e8, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Mar 24 13:23:12 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315947, encodeId=ecbd131594eb9, content=<a href='/topic/show?id=134f14834f2' target=_blank style='color:#2F92EE;'>#PTEN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14834, encryptionId=134f14834f2, topicName=PTEN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Apr 21 05:23:12 CST 2020, time=2020-04-21, status=1, ipAttribution=)]
    2020-10-19 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1884260, encodeId=2687188426049, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Oct 19 21:23:12 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087679, encodeId=a351208e679e8, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Mar 24 13:23:12 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315947, encodeId=ecbd131594eb9, content=<a href='/topic/show?id=134f14834f2' target=_blank style='color:#2F92EE;'>#PTEN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14834, encryptionId=134f14834f2, topicName=PTEN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Apr 21 05:23:12 CST 2020, time=2020-04-21, status=1, ipAttribution=)]
    2021-03-24 liuli5079
  3. [GetPortalCommentsPageByObjectIdResponse(id=1884260, encodeId=2687188426049, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Oct 19 21:23:12 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087679, encodeId=a351208e679e8, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Mar 24 13:23:12 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315947, encodeId=ecbd131594eb9, content=<a href='/topic/show?id=134f14834f2' target=_blank style='color:#2F92EE;'>#PTEN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14834, encryptionId=134f14834f2, topicName=PTEN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Apr 21 05:23:12 CST 2020, time=2020-04-21, status=1, ipAttribution=)]
    2020-04-21 智智灵药

相关资讯

CLIN CANCER RES:AZD8186抑制PI3Kβ调节PTEN缺失肿瘤关键代谢通路

PTEN缺失肿瘤依赖PI3Kβ,可以通过选择性PI3Kβ抑制剂AZD8186进行靶向治疗。但是抑制PI3Kβ的结果尚缺乏完整认识。CLIN CANCER RES近期发表了一篇文章研究这一问题。

Baidu
map
Baidu
map
Baidu
map